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Introduction 
Although an increasing number of drugs have 
been implicated in the aetiology of eosinophilic 
pneumonia characterized by the development of pul- 
monary infiltrates and peripheral blood eosinophilia, 
eosinophilic bronchitis without alveolitis due to 
some pharmacologic agents has not been reported. 
Bucillamine [N-(2-mercapto-2-methylpropionyl)-L- 
cystenine] is a commonly used drug for treatment of 
rheumatoid arthritis in Japan, which has recently 
been added to the growing list of pharmacologic 
agents associated with infiltrative pulmonary lesions. 
A case of eosinophilic bronchitis induced by this drug 
presenting with only severe dry cough is described. 
The results of transbronchoscopic bronchial biopsy, 
a lymphocyte stimulation test, and a challenge test 
supported this diagnosis. 
Case Report 
A 60-year-old woman was admitted to our hospital 
on 19 June 1993 because of severe non-productive 
cough. The chest X-ray films on admission revealed 
no pulmonary infiltrates. Her peripheral blood 
showed marked eosinophilia. Additional history elu- 
cidated that the patient had been taking bucillamine, 
200 mg daily, during the previous 10 weeks for 
treatment of rheumatoid arthritis. 
On physical examination, body temperature was 
35.8”C, blood pressure 130168 mmHg, and pulse rate 
70 beats min - ‘. On ausculation the respiratory 
sound was clear and forced expiratory rhonchi was 
not audible. No heart murmur was noted. There 
was no lymphadenopathy or oedema. Swan neck 
deformity of the fingers was seen. 
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On laboratory findings the arterial blood gas 
levels while breathing room air were: PO, 79.4 torr, 
PCO, 46.2 torr and pH 7.37. The white blood 
cell count was 7700 ~1~ ’ with a differential of 54% 
segmented neutrophils, O”/o stab, 17.9% lymphocytes, 
6.7% monocytes, and 20.2% eosinophils. The haemo- 
globin level was 12.8 g dl - ’ with a haematocrit 
value of 37.2%. The erythrocyte sedimentation 
rate was 10 mm hr- i. The C-reactive protein 
was 0.09 mg dl ~ ‘, IgE level 43 U ml-‘, RA 
0.0 IU ml - i, C, 89.0 mg dl - ’ C, 30.0 mg dl ~ i and 
CH,, 40.6 U ml - ‘. 
The following laboratory values were normal or 
negative: urinalysis, stool examination for ova and 
parasites, serum electrolytes, total protein, albumin, 
and mycobacterial and fungal cultures of the 
sputum. 
The ECG revealed a normal sinus rhythm. The 
chest X-ray film and chest CT scan on admission 
revealed no pulmonary infiltrates. Pulmonary func- 
tion test was almost normal; FVC (1) 2.75, %FVC 
(%) 117.5, FEV, (1) 2.3, %FEV, (%) 126.4, FEV,% 
(%) 83.6, TLC (1) 3.87, %TLC (%) 103.8, %RV (%) 
77.3, %RV TLC ~ ’ (%) 74.6, %DLco (%) 96.0, 
%DLco VA ~ i (Oh) 101.1. Cell differential of the 
sputum showed eosinophilia. 
Bronchoalveolar lavage (BAL) was performed 
using a total volume of 100 ml of sterile saline 
solution (28% recovery). Differential cell analysis 
revealed 82.0% alveolar macrophages, 12.0% 
lymphocytes, 1.0% neutrophils, 5.0% eosinophils, 
and an absolute total cell count of 1.4 x 
10’ cells ml ~ ‘. 
A transbronchoscopic bronchial biopsy (Plate 1) 
from the bifurcation of the right upper lobe bron- 
chus and truncus intermedius showed eosinophil 
infiltration in the propria mucosae. The lympho- 
cyte stimulation test (LST) with bucillamine was 
negative. 
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Plate I A transbronchoscopic bronchial biopsy specimen 
obtained from the bifurcation of the right upper lobe 
bronchus and truncus intermedius showing eosinophil 
infiltration under the bronchial epithelium. 
Regarding the clinical course suggestive of drug- 
induced bronchitis (eosinophilic bronchitis), the 
bucillamine therapy was discontinued. Within 6 days 
the severe cough was resolved and the peripheral 
eosinophils decreased to 4%. As the lymphocyte 
stimulation test with bucillamine was negative, the 
patient was challenged with bucillamine, 100 mg tab- 
let administered every day, under informed consent. 
After 11 days, the patient developed a non- 
productive cough. The white blood cell count 
increased to 7200~11- ’ with 7.4% eosinophils from 
6900 ,ul - ’ with 4.6% eosinophils. Consequently, 
bucillamine was permanently discontinued, then the 
symptoms subsided and laboratory findings returned 
to normal. 
Discussion 
Eosinophilic pneumonia represents a clinical 
manifestation of an immunologic response or aller- 
gic reaction. A number of drugs have been reported 
to be the cause of pulmonary infiltrates (l-3), and 
non-steroidal, anti-inflammatory agents have been 
implicated as aetiologic factors for acute inter- 
stitial pneumonitis (45). Cooper (6) described the 
clinical aspects and pathogenic mechanisms of cyto- 
toxic and non-cytotoxic drug-induced pulmonary 
diseases. 
In eosinophilic pneumonia, eosinophils may infil- 
trate not only the lung parenchyma but also the 
bronchiole and the bronchus, when the parenchymal 
inflammation is severe (7). However eosinophilic 
bronchitis exists not only as a part of eosinophilic 
pneumonia. Although chronic desquamative eosino- 
philic bronchitis is considered to be characteristic of 
bronchial asthma, eosinophilic bronchitis without 
asthma (8) has been reported. Therefore a type of 
eosinophilic bronchitis without alveolitis, so-called 
‘drug-induced bronchitis’, can exist as a manifesta- 
tion of allergic reaction. 
In our case, no pulmonary infiltrates on chest 
X-ray films and chest CT and normal pulmonary 
function including diffusing capacity support the lack 
of alveolitis. 
To evaluate the bronchial reversibility, spirometry 
was performed before and after inhalation of 3OOpg 
of salbutamol sulphate following intravenous injec- 
tion of 250 mg of aminophylline. As the bronchodi- 
lator treatment did not significantly improve FEV, 
(from 2.32-2.39 1) or FVC (from 2.69-2.69 l), it was 
thought that the bronchomotor tone was not 
increased in the patient. 
The airway responsiveness to methacholine was 
assessed according to the method by Cockcroft et al. 
(9). The provocative concentration required to cause 
a 20% fall from the baseline FEV, (PC,,) was 
lOmgml-‘. 
Because the total cell count and percentage of 
lymphocytes of BALF were within the normal limit, 
mild eosinophilia of BALF is thought to have 
resulted from eosinophilic bronchitis rather than 
from eosinophilic pneumonia. The specimens of 
transbronchoscopic bronchial biopsy demonstrated 
eosinophilic infiltration in the bronchial mucosa. 
Thus, eosinophilic bronchitis in our case should be 
distinct from the chronic desquamative eosinophilic 
bronchitis in bronchial asthma, for lack of ‘bronchial 
hyperresponsiveness’ and ‘bronchial reversibility’, 
which are the fundamental factors of bronchial 
asthma (7). Therefore, eosinophils infiltrated in the 
bronchial mucosa may be necessary but not sufficient 
to cause asthma. 
We believe that, in the present case, a bronchial 
hypersensitivity reaction to bucillamine resulted 
in the eosinophilic bronchitis without alveolitis 
presenting with severe non-productive cough and 
blood eosinophilia. Upon cessation of bucillamine 
therapy there was clinical improvement of the illness. 
Rechallenge with bucillamine produced similar 
symptoms and eosinophilia. 
Although extrapulmonary complications of bucil- 
lamine are well known, few cases of bucillamine- 
induced pneumonitis have been reported (10-12) and 
there is no reported case of eosinophilic bronchitis 
without alveolitis due to this agent. 
We described the first case of eosinophilic bron- 
chitis without bronchial smooth muscle contraction 
nor alveolitis presented with severe non-productive 
cough caused by bucillamine. 
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